MABS

单克隆抗体是一个多学科的杂志，致力于艺术和科学抗体的研究和发展。该杂志具有强大的科学和医学重点，但也努力为更广泛的读者服务。因此，科学家、临床研究人员、医生以及更广泛的mAb社区都对这些文章感兴趣，包括我们的读者，他们涉及技术转让、法律问题、投资、战略规划和治疗的监管。mAbs出版相关的和及时的原始研究，以及权威的综述、评论和观点，为mAbs中提出的工作和其他地方发表的关键结果提供上下文。原始研究论文可能涵盖抗体领域的所有重要主题，包括对非抗体为基础的靶向蛋白的研究。欢迎对抗体研发的任何方面进行评论、评论和展望。相关主题包括(但不限于)：抗体工程及选择目标与癌症、免疫介导性疾病和其他疾病相关抗体的非临床研究，如作用机理研究、动物安全性和有效性研制造业临床研究抗体疗法的监管审查审批后的主题，如定价、报销和市场专利抗体疗法的新兴市场，包括中国和印度所有提交的稿件都要经过编辑人员的初步评估，如果发现适合进一步考虑，稿件将由独立的、匿名的专家评审人员提交给同行评审。所有同行评审都是单盲的。提交请访问http://www.editorialmanager.com/mabs

mAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics. mAbs publishes relevant and timely original research, as well as authoritative overviews, commentary and perspectives providing context for the work presented in mAbs and for key results published elsewhere. Original research papers may cover all topics important in the antibody field, including studies of targeted proteins that are not antibody-based. Reviews, commentaries and perspectives on any aspect of antibody R&D are welcome. Relevant topics include (but are not be limited to): Antibody engineering and selection Targets relevant to cancer, immune-mediated disorders, and other diseasesNon-clinical studies of antibodies, e.g., mechanism of action studies, safety and efficacy studies in animalsManufacturingClinical studiesRegulatory review of antibody therapeuticsPost-approval topics, e.g., pricing, reimbursement and marketsPatentsEmerging markets for antibody therapeutics, including China and IndiaAll submitted manuscripts are subjected to initial evaluation by the editorial staff, and, if found suitable for further consideration, manuscripts are sent to peer review by independent, anonymous expert referees. All peer review is single blind. Submission is online at http://www.editorialmanager.com/mabs